Home>Topics>>Pluristem ([[PSTI]] +2.5%) says the FDA has acknowledged that aplastic anemia is a rare disease, confirming that potential treatments for the condition are eligible for orphan drug status. However, ...
Pluristem ([[PSTI]] +2.5%) says the FDA has acknowledged that aplastic anemia is a rare disease, confirming that potential treatments for the condition are eligible for orphan drug status. However, ...
Pluristem ( PSTI +2.5% ) says the FDA has acknowledged that aplastic anemia is a rare disease, confirming that potential treatments for the condition are eligible for orphan drug status. However, it also has requested that PSTI provide additional information and data for further analysis before the ...
Read the rest of this article on SeekingAlpha.com: SA Currents